Rapid discrimination of multiple myeloma patients by artificial neural networks coupled with mass spectrometry of peripheral blood plasma.
Aged
Aged, 80 and over
Artificial Intelligence
/ statistics & numerical data
Bone Marrow
/ metabolism
Case-Control Studies
Datasets as Topic
Female
Humans
Immunoglobulins
/ blood
Male
Metabolic Networks and Pathways
Metabolome
Middle Aged
Multiple Myeloma
/ blood
Neural Networks, Computer
Principal Component Analysis
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
28 05 2019
28 05 2019
Historique:
received:
21
01
2019
accepted:
09
05
2019
entrez:
30
5
2019
pubmed:
30
5
2019
medline:
21
10
2020
Statut:
epublish
Résumé
Multiple myeloma (MM) is a highly heterogeneous disease of malignant plasma cells. Diagnosis and monitoring of MM patients is based on bone marrow biopsies and detection of abnormal immunoglobulin in serum and/or urine. However, biopsies have a single-site bias; thus, new diagnostic tests and early detection strategies are needed. Matrix-Assisted Laser Desorption/Ionization Time-of Flight Mass Spectrometry (MALDI-TOF MS) is a powerful method that found its applications in clinical diagnostics. Artificial intelligence approaches, such as Artificial Neural Networks (ANNs), can handle non-linear data and provide prediction and classification of variables in multidimensional datasets. In this study, we used MALDI-TOF MS to acquire low mass profiles of peripheral blood plasma obtained from MM patients and healthy donors. Informative patterns in mass spectra served as inputs for ANN that specifically predicted MM samples with high sensitivity (100%), specificity (95%) and accuracy (98%). Thus, mass spectrometry coupled with ANN can provide a minimally invasive approach for MM diagnostics.
Identifiants
pubmed: 31138828
doi: 10.1038/s41598-019-44215-1
pii: 10.1038/s41598-019-44215-1
pmc: PMC6538619
doi:
Substances chimiques
Immunoglobulins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7975Références
PLoS One. 2018 Aug 10;13(8):e0202045
pubmed: 30096165
J Transl Med. 2010 Jul 11;8:66
pubmed: 20618994
J Am Soc Mass Spectrom. 2017 Mar;28(3):419-427
pubmed: 27995502
Anat Rec (Hoboken). 2009 Apr;292(4):604-10
pubmed: 19301277
Bioinformatics. 2012 Sep 1;28(17):2270-1
pubmed: 22796955
Dis Markers. 2006;22(4):245-55
pubmed: 17124346
Proteomics. 2003 May;3(5):601-9
pubmed: 12748940
J Microbiol Methods. 2000 Dec 1;43(1):3-31
pubmed: 11084225
Klin Onkol. 2017 Summer;30(Supplementum2):35-42
pubmed: 28903569
Clin Cancer Res. 2013 Sep 1;19(17):4770-9
pubmed: 23873687
Lab Invest. 2004 Jul;84(7):845-56
pubmed: 15107802
Blood. 2018 Aug 9;132(6):587-597
pubmed: 29884741
J Transl Med. 2009 Jul 13;7:60
pubmed: 19594898
PLoS One. 2016 Jan 28;11(1):e0147414
pubmed: 26821236
BMC Cancer. 2012 Sep 19;12:415
pubmed: 22992303
Leukemia. 2009 Jan;23(1):3-9
pubmed: 18971951
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
Stem Cells Transl Med. 2018 Jan;7(1):109-114
pubmed: 29248004
Clin Chem. 2000 Aug;46(8 Pt 2):1230-8
pubmed: 10926917
Urol Oncol. 2004 Jul-Aug;22(4):337-43
pubmed: 15283893
Chin Med J (Engl). 2015 Apr 20;128(8):1108-13
pubmed: 25881608
Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12343-8
pubmed: 14523236
Int J Hematol. 2012 Jun;95(6):668-74
pubmed: 22539364
Clin Cancer Res. 2005 Sep 15;11(18):6550-7
pubmed: 16166432
BMC Genomics. 2014 Oct 17;15:904
pubmed: 25322877
Klin Onkol. 2017 Summer;30(Supplementum2):13-20
pubmed: 28903565
Cell J. 2017 Spring;19(Suppl 1):44-54
pubmed: 28580307
Ann Oncol. 2010 Oct;21 Suppl 7:vii143-50
pubmed: 20943607